Key Highlights

  • Loss per share was USD 0.53, against an estimate of a USD 0.47 loss.
  • Sales were USD 404.6 thousand, against an estimate of USD 810 thousand.
  • Net loss was USD 4.56 million, against USD 4.19 million a year earlier.
  • Cash and cash equivalents were USD 23.91 million at September 30.

Femasys (NASDAQ:FEMY) lost USD 0.53 per share in the third quarter of 2026, against an estimated loss of USD 0.47. Sales were USD 404,597, against an estimate of USD 810 thousand and USD 729,394 in the third quarter of 2025. The net loss was USD 4,564,815, against USD 4,194,821, and the loss from operations was USD 4,450,010, against USD 3,653,768. The figures come from the company's quarterly filing for the period ended September 30, 2026.

Where Costs Moved

Cost of sales, excluding Depreciation expense, was USD 187,496, against USD 293,838. Research and Development expenses were USD 1,942,927, against USD 1,382,022, and sales and Marketing expenses were USD 943,002, against USD 1,143,805. General and administrative expenses were USD 1,704,091, against USD 1,477,800, and depreciation and amortization was USD 77,091, against USD 85,697.

Total operating expenses were USD 4,667,111, against USD 4,089,324. Interest income was USD 85,610, against USD 17,315.

The Nine-Month Picture

For the nine months ended September 30, 2026, sales were USD 1,161,313, against USD 1,479,926, and the loss from operations was USD 13,739,417, against USD 12,965,941. Total operating expenses were USD 14,412,192, against USD 13,876,592.

The nine-month net loss was USD 8,187,810, against USD 14,677,582, and the period included a USD 1,732,413 change in the Fair Value of a conversion option liability. Interest income was USD 155,131, against USD 53,488, and net cash used in Operating Activities was USD 12,896,701, against USD 14,505,325.

Cash, Assets and Liquidity

Cash and cash equivalents were USD 23,913,946, against USD 9,266,353 at the prior Balance Sheet date. Accounts receivable, net, were USD 233,778, against USD 616,600, and inventory was USD 6,166,371, against USD 5,740,249. Prepaid and other current assets were USD 893,098, against USD 833,133. Total assets were USD 35,087,658, against USD 20,724,177.

The filing says the company believes its cash and cash equivalents of USD 23,913,946 as of September 30, 2026 provide enough Liquidity to fund planned operations, Capital requirements and other obligations for at least twelve months after the financial statements are issued. It also says all share and per share information has been retroactively adjusted for the 1-for-20 Reverse Stock Split in every period presented.

Total share-based compensation expense was USD 190,216 for the quarter, against USD 174,514, and USD 552,644 for the nine months, against USD 723,722. Paid-in-kind interest and amortization of Debt issuance costs and discount on the 2023 and 2025 notes were USD 196,427 for the quarter, against USD 426,541. Share-based compensation was USD 33,630 in research and development, against USD 65,625, USD 11,529 in sales and marketing, against USD 19,047, and USD 145,057 in general and administrative, against USD 89,842.

The Quarter in Brief

Femasys reported a third quarter 2026 loss of USD 0.53 per share, sales of USD 404,597 and a net loss of USD 4,564,815. Cash and cash equivalents were USD 23,913,946 at September 30, 2026.